NASDAQ:IVTY - Invuity Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.39
+0.30 (1.20%)
Get New Invuity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVTY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVTY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Invuity in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.39.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Invuity. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/17/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
i
9/12/2018SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by R. Newitter at SVB Leerink LLC
9/11/2018Stifel NicolausDowngradeBuy ➝ HoldLow
i
9/11/2018Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralMedium
i
9/11/2018William BlairDowngradeOutperform ➝ Market PerformMedium
i
Rating by B. Weinstein at William Blair
5/4/2018Stifel NicolausLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00High
i
2/14/2018Northland SecuritiesReiterated RatingBuy$6.00Medium
i
11/10/2017Piper Jaffray CompaniesReiterated RatingBuy$12.00N/A
i
9/26/2017Northland SecuritiesReiterated RatingBuy$13.00Low
i
Rating by Suraj Kalia at Northland Securities
7/26/2017Piper Jaffray CompaniesReiterated RatingBuy$10.00High
i
6/13/2017Northland SecuritiesSet Price TargetBuy$13.00High
i
Rating by Suraj Kalia at Northland Securities
5/23/2017William BlairReiterated RatingBuyLow
i
Rating by Kaila Krum at William Blair
5/16/2017Northland SecuritiesReiterated RatingBuy$13.00Low
i
5/8/2017Northland SecuritiesReiterated RatingBuy$13.00Low
i
4/27/2017Stifel NicolausReiterated RatingBuy ➝ Buy$9.00 ➝ $10.00High
i
4/23/2017Northland SecuritiesReiterated RatingOutperform$13.00Medium
i
2/15/2017Stifel NicolausReiterated RatingBuy$8.00 ➝ $9.00N/A
i
9/19/2016Lake Street CapitalInitiated CoverageBuy$18.00 ➝ $18.00N/A
i
Rating by B. Jackson at Lake Street Capital
8/29/2016Craig HallumInitiated CoverageBuy$25.00N/A
i
7/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$12.00N/A
i
6/23/2016SVB LeerinkReiterated RatingBuy$15.00N/A
i
(Data available from 3/8/2016 forward)
Invuity logo
Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Read More

Today's Range

Now: $7.39
$7.39
$7.39

50 Day Range

MA: N/A

52 Week Range

Now: $7.39
$2.35
$9.55

Volume

N/A

Average Volume

324,995 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Invuity?

The following Wall Street research analysts have issued research reports on Invuity in the last twelve months:
View the latest analyst ratings for IVTY.

What is the current price target for Invuity?

0 Wall Street analysts have set twelve-month price targets for Invuity in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Invuity in the next year.
View the latest price targets for IVTY.

What is the current consensus analyst rating for Invuity?

Invuity currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IVTY.

What other companies compete with Invuity?

How do I contact Invuity's investor relations team?

Invuity's physical mailing address is 444 DE HARO STREET, San Francisco CA, 94107. The medical instruments supplier's listed phone number is 415-655-2100 and its investor relations email address is [email protected] The official website for Invuity is www.invuity.com.